These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An insight into the pathophysiology of thrombosis in antiphospholipid syndrome. Palomo IG; Segovia FM; Alarcon ML; Fuentes BY; Pereira JG; Rojas A; Forastiero R Front Biosci; 2007 May; 12():3093-103. PubMed ID: 17485284 [TBL] [Abstract][Full Text] [Related]
7. The antiphospholipid syndrome: from pathophysiology to treatment. Negrini S; Pappalardo F; Murdaca G; Indiveri F; Puppo F Clin Exp Med; 2017 Aug; 17(3):257-267. PubMed ID: 27334977 [TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of thrombosis and potential targeted therapies in antiphospholipid syndrome. Amengual O; Atsumi T; Koike T Curr Vasc Pharmacol; 2011 Sep; 9(5):606-18. PubMed ID: 21692741 [TBL] [Abstract][Full Text] [Related]
9. The role of beta 2-glycoprotein I-dependent lupus anticoagulants in the pathogenesis of the antiphospholipid syndrome. Arnout J Verh K Acad Geneeskd Belg; 2000; 62(5):353-72. PubMed ID: 11144685 [TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanisms of "Antiphospholipid Antibodies" and Their Paradoxical Role in the Pathogenesis of "Seronegative APS". Misasi R; Longo A; Recalchi S; Caissutti D; Riitano G; Manganelli V; Garofalo T; Sorice M; Capozzi A Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33182499 [TBL] [Abstract][Full Text] [Related]
11. Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Mondejar R; González-Rodríguez C; Toyos-Sáenz de Miera FJ; Melguizo-Madrid E; Zohoury N; Mahler M; Romero Losquiño I; Fabiani F Clin Chim Acta; 2014 Apr; 431():174-8. PubMed ID: 24522162 [TBL] [Abstract][Full Text] [Related]
12. Alarmin HMGB1 and Soluble RAGE as New Tools to Evaluate the Risk Stratification in Patients With the Antiphospholipid Syndrome. Manganelli V; Truglia S; Capozzi A; Alessandri C; Riitano G; Spinelli FR; Ceccarelli F; Mancuso S; Garofalo T; Longo A; Valesini G; Sorice M; Conti F; Misasi R Front Immunol; 2019; 10():460. PubMed ID: 30923525 [TBL] [Abstract][Full Text] [Related]
13. Pyroptosis-triggered pathogenesis: New insights on antiphospholipid syndrome. Tan Y; Liu Q; Li Z; Yang S; Cui L Front Immunol; 2023; 14():1155222. PubMed ID: 37063905 [TBL] [Abstract][Full Text] [Related]
14. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Forastiero R; Martinuzzo M Lupus; 2008 Oct; 17(10):872-7. PubMed ID: 18827051 [TBL] [Abstract][Full Text] [Related]
15. Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome. Fierro JJ; Velásquez M; Cadavid AP; de Leeuw K Am J Reprod Immunol; 2022 Jan; 87(1):e13509. PubMed ID: 34738282 [TBL] [Abstract][Full Text] [Related]
16. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Benhamou Y; Bellien J; Armengol G; Brakenhielm E; Adriouch S; Iacob M; Remy-Jouet I; Le Cam-Duchez V; Monteil C; Renet S; Jouen F; Drouot L; Menard JF; Borg JY; Thuillez C; Boyer O; Levesque H; Richard V; Joannidès R Arthritis Rheumatol; 2014 Nov; 66(11):3210-20. PubMed ID: 25047402 [TBL] [Abstract][Full Text] [Related]